By Yafo Life Sciences
December 26th, 2021 (Shanghai) — We are glad to announce that Wenzhi Tian, the CEO of ImmuneOnco Biopharmaceuticals, has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About ImmuneOnco Biopharmaceuticals
ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is a clinical-stage biopharmaceutical company dedicated to development and commercialization of innovative cancer immunotherapy.
The company has established several solid platforms harnessing both innate and adaptive immune cells. Macrophages play a critical role in fighting cancer through phagocytosis followed by presenting of tumor antigen to T cell. However cancer cells are smart and can always find a way to evade the surveillance, such as by over-expressing immune checkpoints including CD47.
ImmuneOnco takes the advantage of the IP-protected SIRPa-domain to develop the mAb-Trap format by which several bispecific recombinant antibody-receptor proteins have been developed that simultaneously targeting CD47 and other tumor antigen (TA) such as CD20, Her2, PD-L1, new targets, etc.
About the speaker
Dr. Wenzhi Tian is CEO of ImmuneOnco and has extensive antibody drug development experiences obtained from his career at ImClone (Eli Lilly) and the pharma industry.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: